Online citations, reference lists, and bibliographies.
← Back to Search

In Vivo Prevalence Of Azidothymidine (AZT) Resistance Mutations In An AIDS Patient Before And After AZT Therapy.

J. Fitzgibbon, R. Howell, T. Schwartzer, D. Gocke, D. Dubin
Published 1991 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
In order to examine the in vivo prevalence of AZT resistance mutations in AID patients after long-term therapy we amplified, by polymerase chain reaction (PCR), a 654 bp pol gene fragment from peripheral blood mononuclear cell DNA samples from a patient before, and 19 months after, the start of AZT therapy. PCR products from each sample were cloned and 9 clones from each sample were sequenced. Seven of 9 clones from the post-AZT sample, but none from the pre-AZT sample, contained an amino acid substitution (Thr215 to Tyr) requiring two nucleotide changes within the same codon (ACC to TAC). This change had previously been shown by Larder and Kemp (Science, 246:1155-1158, 1989) to correlate with partial AZT resistance of virus isolates. In colony hybridizations using synthetic oligonucleotides corresponding to the mutant and wild-type sequences, 22 of 22 clones from the pre-AZT sample hybridized only to the wild-type probe while 21 of 26 clones from the post-AZT sample hybridized only to the mutant. Clinically, this patient remains well, indicating that while Tyr215 may be the first amino acid substitution leading to resistance, it alone does not appear to have significantly influenced the clinical status of this patient.
This paper references

This paper is referenced by
A counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selection
P. Lemey (2012)
Virologic failure and HIV-1 drug resistance among antiretroviral therapy recipients in an urban resource-limited setting - the South African Virologic Evaluation (SAVE) study
Z. El-Khatib (2011)
Jan Sahai (2011)
Not so different after all: a comparison of methods for detecting amino acid sites under selection.
Sergei L. Kosakovsky Pond (2005)
Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment
M. Zazzi (2005)
A perspective of the history of HAART
D. Konopnicki (2004)
HIV-1 Reverse Transcriptase Mutations Found in a Drug-Experienced Patient Confer Reduced Susceptibility to Multiple Nucleoside Reverse Transcriptase Inhibitors
J. Fitzgibbon (2001)
Alternative approaches for the application of ribozymes as gene therapies for retroviral infections.
T. Campbell (1995)
HIV resistance to reverse transcriptase inhibitors
E. D. Clercq (1994)
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group
D. Mayers (1994)
The Polymerase Chain Reaction
K. Mullis (1994)
Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.
A. Erice (1993)
Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs
J. Fitzgibbon (1993)
Competitive inhibitors of human immunodeficiency virus reverse transcriptase
R. Schinazi (1993)
An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield
Z. Xing (1993)
A new type of G-->A hypermutation affecting human immunodeficiency virus.
J. Fitzgibbon (1993)
Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation.
J. Fitzgibbon (1993)
Dynamic changes in HIV‐1 quasispecies from azidothymidine (AZT)‐treated patients
J. Wahlberg (1992)
Oncogenes and cell proliferation
Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
K. De Vreese (1992)
Development of In Vitro resistance to zidovudine is likely to be clinically significant
G. Tudor-Williams (1992)
Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.
J. Fitzgibbon (1992)
Semantic Scholar Logo Some data provided by SemanticScholar